頁籤選單縮合
題名 | 腫瘤壞死因子阻斷劑類藥品之評估=Evaluaion of Tumor Necrosis Factor Alpha Blockers |
---|---|
作者 | 梁雅惠; 吳淑娟; 陳立奇; | 書刊名 | 藥學雜誌 |
卷期 | 33:2=131 2017.06[民106.06] |
頁次 | 頁50-55 |
分類號 | 418.31 |
關鍵詞 | 腫瘤壞死因子阻斷劑類藥品; 結核病; 病毒性肝炎; TNF-α blockers; Tuberculosis; Virus hepatitis; |
語文 | 中文(Chinese) |
中文摘要 | 目的:腫瘤壞死因子阻斷劑類可能導致病人免疫力降低,進而造成帶有結核桿菌 者的結核病發作及病毒性肝炎復發。本研究目的為監控院內使用腫瘤壞死因子阻斷劑 在治療中帶來的風險,是否定期監測,提升病人之用藥安全。方法:以回溯性進行研 究,分析101年8月1日至102年12月31日使用腫瘤壞死因子阻斷劑類藥品的病人風險。 結果:收集160位病人,第一次使用腫瘤壞死因子阻斷劑類藥品有55位 (34.4%),使 用生物製劑前有檢查 TST 者有29位 (52.7%),檢查胸部X光者僅有3位 (5.5%),使用後 造成 ALT 上升有10位 (6.3%)。結論:此次研究中發現部分案例雖非B型或C型肝炎患 者,但仍有肝功能指數 ALT 上升情形,加強對風濕免疫科醫師宣導進行風險評估及 必要檢查,以避免發生危害。 |
英文摘要 | OBJECTIVES: Tumor Necrosis Factor-alpha (TNFα) blockers might reduce patients’ immune system, further resulting in the progression of latent tuberculosis patients and relapse of viral hepatitis. Our study is to monitor the possible risk of TNFα-blockers treatment in the hospital and to improve the drug safety for patients. METHODS: We retrospectively identified the risk of patients, who had undergone the drug treatment of TNFα-blockers from Aug 1st, 2012 to Dec, 31st, 2013. RESULTS: The data of total 160 patients were recorded. Among them, 55 patients (34.4%) were the first time use of TNFα-blockers, 29 patients (52.7%) received the TST test before TNFα-blockers treatment, only 3 patients (5.5%) received chest X-Ray exam and 10 patients (6.3%) had an elevated ALT level after TNFα-blockers treatment. CONCLUSIONS: In this study we found that some cases had an elevated ALT level although they are not hepatitis B or C patients. To avoid the possible endanger, it is important to suggest AIR doctors to perform risk evaluations and necessary examinations. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。